Citation

Goodman AJ, Ajello CW, Worm K, Le Bourdonnec B, Savolainen MA, O'Hare H, Cassel JA, Stabley GJ, Dehaven RN, Labuda CJ, Koblish M, Little PJ, Brogdon BL, Smith SA, Dolle RE. Bioorg. Med. Chem. Lett. 2009; 19(2): 309-313.

Copyright

(Copyright © 2009, Elsevier Publishing)

DOI

10.1016/j.bmcl.2008.11.091

PMID

19091565

Abstract

Previous research within our laboratories identified sulfamoyl benzamides as novel cannabinoid receptor ligands. Optimization of the amide linkage led to the reverse amide 40. The compound exhibited robust antiallodynic activity in a rodent pain model when administered intraperitoneally. Efficacy after oral administration was observed only when ABT, a cytochrome P450 suicide inhibitor, was coadministered.

Language: en

Keywords

Animals; Benzamides; Pain; Receptor, Cannabinoid, CB2; Rodentia